Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Topical BRAF inhibitor relieves EGFR-induced acneiform eruption

07 Jul 2025 bởi

LUT014 gel, a novel, small-molecule, topical formulation of a BRAF inhibitor, relieves acneiform rash toxicities from anti-EGFR therapies, findings from a phase II study suggest.

Topical BRAF inhibitor relieves EGFR-induced acneiform eruption

07 Jul 2025

Hormone therapy's impact on young-onset breast cancer risk varies by type

06 Jul 2025

New research shows that using oestrogen hormone therapy alone may reduce the risk of young-onset breast cancer, while combining it with progestin could result in a risk increase among women with intact uterus and ovaries.

Hormone therapy's impact on young-onset breast cancer risk varies by type

06 Jul 2025

CDK4/6 inhibitor-induced liver injury common in breast cancer

05 Jul 2025 bởi

Liver injury occurs in around one in 20 patients treated with cyclin-dependent kinase 4/6 inhibitors for metastatic breast cancer, according to a multicentre retrospective study in Spain.

CDK4/6 inhibitor-induced liver injury common in breast cancer

05 Jul 2025

DESTINY-Breast09: T-DXd plus pertuzumab improves PFS in HER2+ breast cancer

05 Jul 2025 bởi

Treatment with trastuzumab deruxtecan (T-DXd) plus pertuzumab significantly improved progression-free survival (PFS) in patients with HER2+ advanced/metastatic breast cancer (a/mBC) compared with standard of care in the first-line setting, according to a planned interim analysis of the phase III DESTINY-Breast09 trial presented at ASCO 2025.

DESTINY-Breast09: T-DXd plus pertuzumab improves PFS in HER2+ breast cancer

05 Jul 2025

First-line benmelstobart–anlotinib combo yields PFS gain in advanced PD-L1-positive NSCLC

03 Jul 2025 bởi

In the first-line treatment of patients with advanced PD-L1–positive non–small cell lung cancer (NSCLC), the combination of the anti-PD-L1 monoclonal antibody benmelstobart plus the multikinase inhibitor anlotinib prolongs progression-free survival (PFS) compared with pembrolizumab monotherapy, according to the phase III CAMPASS study conducted in China.

First-line benmelstobart–anlotinib combo yields PFS gain in advanced PD-L1-positive NSCLC

03 Jul 2025

Psilocybin eases depression, with minor impact on brain responsiveness

03 Jul 2025

Treatment with psilocybin results in significant improvements in depressive symptoms, and its use only shows a minor effect on brain responsiveness to emotional stimuli.

Psilocybin eases depression, with minor impact on brain responsiveness

03 Jul 2025

Ropeginterferon α-2b extends benefit to another rare blood cancer

03 Jul 2025 bởi

Topline results of the phase III SURPASS-ET trial show the superior efficacy of ropeginterferon α-2b (ropeg) compared with anagrelide as second-line (2L) treatment for high-risk essential thrombocythaemia (ET), a rare blood cancer that may progress to myelofibrosis or acute myeloid leukaemia.

Ropeginterferon α-2b extends benefit to another rare blood cancer

03 Jul 2025

Utidelone plus bevacizumab shows promise in ERBB2-negative MBC

03 Jul 2025

Combination treatment with utidelone plus bevacizumab has demonstrated therapeutic potential in patients with ERBB2-negative metastatic breast cancer (MBC) and active brain metastases in a single-arm, phase II study conducted in China.

Utidelone plus bevacizumab shows promise in ERBB2-negative MBC

03 Jul 2025

AMPLITUDE: Niraparib plus AAP improves survival in mCSPC patients with gene mutations

02 Jul 2025 bởi

The combination of niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) results in significant improvements in radiographic progression-free survival (rPFS) and time to symptomatic progression (TSP) in metastatic castration-sensitive prostate cancer (mCSPC) patients with alterations in homologous recombination repair (HRR) genes, as shown by the results of the phase III AMPLITUDE trial.

AMPLITUDE: Niraparib plus AAP improves survival in mCSPC patients with gene mutations

02 Jul 2025

Ceftazidime-avibactam, ceftolozane-tazobactam safe for use in children

02 Jul 2025

Treatment with either ceftazidime-avibactam (CAZ/AVI) or ceftolozane-tazobactam (C/T) is well tolerated and effective in children infected with Gram-negative pathogens resistant to carbapenems, a recent study has shown.

Ceftazidime-avibactam, ceftolozane-tazobactam safe for use in children

02 Jul 2025

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

Topical BRAF inhibitor relieves EGFR-induced acneiform eruption

Topical BRAF inhibitor relieves EGFR-induced acneiform eruption

Hormone therapy's impact on young-onset breast cancer risk varies by type

Hormone therapy's impact on young-onset breast cancer risk varies by type

CDK4/6 inhibitor-induced liver injury common in breast cancer

CDK4/6 inhibitor-induced liver injury common in breast cancer

DESTINY-Breast09: T-DXd plus pertuzumab improves PFS in HER2+ breast cancer

DESTINY-Breast09: T-DXd plus pertuzumab improves PFS in HER2+ breast cancer

First-line benmelstobart–anlotinib combo yields PFS gain in advanced PD-L1-positive NSCLC

First-line benmelstobart–anlotinib combo yields PFS gain in advanced PD-L1-positive NSCLC

Psilocybin eases depression, with minor impact on brain responsiveness

Psilocybin eases depression, with minor impact on brain responsiveness

Ropeginterferon α-2b extends benefit to another rare blood cancer

Ropeginterferon α-2b extends benefit to another rare blood cancer

Utidelone plus bevacizumab shows promise in ERBB2-negative MBC

Utidelone plus bevacizumab shows promise in ERBB2-negative MBC

AMPLITUDE: Niraparib plus AAP improves survival in mCSPC patients with gene mutations

AMPLITUDE: Niraparib plus AAP improves survival in mCSPC patients with gene mutations

Ceftazidime-avibactam, ceftolozane-tazobactam safe for use in children

Ceftazidime-avibactam, ceftolozane-tazobactam safe for use in children